Background MRI-based diffusion-weighted imaging (DWI) visualizes the local differences in water diffusion in vivo. The prognostic value of DWI signal intensities on the source images and apparent diffusion coefficient (ADC) maps respectively has not yet been studied in brain metastases (BM). Methods We included into this retrospective analysis all patients operated for single BM at our institution between 2002 and 2010, in whom presurgical DWI and BM tissue samples were available. We recorded relevant clinical data, assessed DWI signal intensity and apparent diffusion coefficient (ADC) values and performed histopathological analysis of BM tissues. Statistical analyses including uni- and multivariate survival analyses were performed. Results 65 patients (34 female, 31 male) with a median overall survival time (OS) of 15 months (range 0–99 months) were available for this study. 19 (29.2%) patients presented with hyper-, 3 (4.6%) with iso-, and 43 (66.2%) with hypointense DWI. ADCmean values could be determined in 32 (49.2%) patients, ranged from 456.4 to 1691.8*10？6 mm2/s (median 969.5) and showed a highly significant correlation with DWI signal intensity. DWI hyperintensity correlated significantly with high amount of interstitial reticulin deposition. In univariate analysis, patients with hyperintense DWI (5 months) and low ADCmean values (7 months) had significantly worse OS than patients with iso/hypointense DWI (16 months) and high ADCmean values (30 months), respectively. In multivariate survival analysis, high ADCmean values retained independent statistical significance. Conclusions Preoperative DWI findings strongly and independently correlate with OS in patients operated for single BM and are related to interstitial fibrosis. Inclusion of DWI parameters into established risk stratification scores for BM patients should be considered.
References
[1]
Frisk G, Svensson T, Backlund LM, Lidbrink E, Blomqvist P, et al. (2012) Incidence and time trends of brain metastases admissions among breast cancer patients in Sweden. Br J Cancer 106: 1850–1853.
[2]
Schouten LJ, Rutten J, Huveneers HA, Twijnstra A (2002) Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94: 2698–2705.
[3]
Soffietti R, Cornu P, Delattre JY, Grant R, Graus F, et al. (2006) EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force. Eur J Neurol 13: 674–681.
[4]
Preusser M, Winkler F, Collette L, Haller S, Marreaud S, et al. (2012) Trial design on prophylaxis and treatment of brain metastases: Lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. Eur J Cancer: in press.
[5]
Preusser M, Berghoff AS, Schadendorf D, Lin NU, Stupp R (2012) Brain metastasis: opportunity for drug development? Curr Opin Neurol: in press.
[6]
Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W (2008) A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 70: 510–514.
[7]
Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, et al. (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37: 745–751.
[8]
Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, et al. (2012) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30: 419–425.
[9]
Berghoff AS, Bago-Horvath Z, Ilhan-Mutlu A, Magerle M, Dieckmann K, et al. (2012) Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors. Br J Cancer 107: 1454–1458.
[10]
Gaspar LE, Gutin PH, Rogers L, Schneider JF, Larson D, et al. (2000) Pre-irradiation evaluation and management of brain metastases. American College of Radiology. ACR Appropriateness Criteria. Radiology 215 Suppl: 1105–1110
[11]
Calli C, Kitis O, Yunten N, Yurtseven T, Islekel S, et al. (2006) Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors. Eur J Radiol 58: 394–403.
[12]
Lee EK, Lee EJ, Kim MS, Park HJ, Park NH, et al. (2012) Intracranial metastases: spectrum of MR imaging findings. Acta Radiol. In press.
[13]
Arvinda HR, Kesavadas C, Sarma PS, Thomas B, Radhakrishnan VV, et al. (2009) Glioma grading: sensitivity, specificity, positive and negative predictive values of diffusion and perfusion imaging. J Neurooncol 94: 87–96.
[14]
Fan GG, Deng QL, Wu ZH, Guo QY (2006) Usefulness of diffusion/perfusion-weighted MRI in patients with non-enhancing supratentorial brain gliomas: a valuable tool to predict tumour grading? Br J Radiol 79: 652–658.
[15]
Sugahara T, Korogi Y, Kochi M, Ikushima I, Shigematu Y, et al. (1999) Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 9: 53–60.
[16]
Boxerman JL, Rogg JM, Donahue JE, Machan JT, Goldman MA, et al. (2010) Preoperative MRI evaluation of pituitary macroadenoma: imaging features predictive of successful transsphenoidal surgery. AJR Am J Roentgenol 195: 720–728.
[17]
Wang S, Kim S, Chawla S, Wolf RL, Knipp DE, et al. (2011) Differentiation between glioblastomas, solitary brain metastases, and primary cerebral lymphomas using diffusion tensor and dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 32: 507–514.
[18]
Pillai S, Singhal A, Byrne AT, Dunham C, Cochrane DD, et al. (2011) Diffusion-weighted imaging and pathological correlation in pediatric medulloblastomas-“They are not always restricted!”. Childs Nerv Syst 27: 1407–1411.
[19]
Curvo-Semedo L, Lambregts DM, Maas M, Beets GL, Caseiro-Alves F, et al. (2012) Diffusion-weighted MRI in rectal cancer: apparent diffusion coefficient as a potential noninvasive marker of tumor aggressiveness. J Magn Reson Imaging 35: 1365–1371.
[20]
Aoyagi T, Shuto K, Okazumi S, Hayano K, Satoh A, et al. (2012) Apparent diffusion coefficient correlation with oesophageal tumour stroma and angiogenesis. Eur Radiol 22: 1172–1177.
[21]
Nakajo M, Kajiya Y, Kaneko T, Kaneko Y, Takasaki T, et al. (2010) FDG PET/CT and diffusion-weighted imaging for breast cancer: prognostic value of maximum standardized uptake values and apparent diffusion coefficient values of the primary lesion. Eur J Nucl Med Mol Imaging 37: 2011–2020.
[22]
Wohrer A, Waldhor T, Heinzl H, Hackl M, Feichtinger J, et al. (2009) The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol 95: 401–411.
[23]
Preusser M, Hoeftberger R, Woehrer A, Gelpi E, Kouwenhoven M, et al. (2012) Prognostic value of Ki67 index in anaplastic oligodendroglial tumours–a translational study of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Histopathology 60: 885–894.
[24]
Ohno Y, Koyama H, Yoshikawa T, Matsumoto K, Aoyama N, et al. (2012) Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy. AJR Am J Roentgenol 198: 75–82.
[25]
Barajas RF Jr, Rubenstein JL, Chang JS, Hwang J, Cha S (2010) Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma. AJNR Am J Neuroradiol 31: 60–66.
[26]
Duygulu G, Ovali GY, Calli C, Kitis O, Yunten N, et al. (2010) Intracerebral metastasis showing restricted diffusion: correlation with histopathologic findings. Eur J Radiol 74: 117–120.
[27]
Hayashida Y, Hirai T, Morishita S, Kitajima M, Murakami R, et al. (2006) Diffusion-weighted imaging of metastatic brain tumors: comparison with histologic type and tumor cellularity. AJNR Am J Neuroradiol 27: 1419–1425.
[28]
Langley RR, Fidler IJ (2011) The seed and soil hypothesis revisited–the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer 128: 2527–2535.
[29]
Moorman AM, Vink R, Heijmans HJ, van der Palen J, Kouwenhoven EA (2012) The prognostic value of tumour-stroma ratio in triple-negative breast cancer. Eur J Surg Oncol 38: 307–313.
[30]
de Kruijf EM, van Nes JG, van de Velde CJ, Putter H, Smit VT, et al. (2011) Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. Breast Cancer Res Treat 125: 687–696.
[31]
Mesker WE, Junggeburt JM, Szuhai K, de Heer P, Morreau H, et al. (2007) The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Cell Oncol 29: 387–398.
[32]
Silvera S, Oppenheim C, Touze E, Ducreux D, Page P, et al. (2005) Spontaneous intracerebral hematoma on diffusion-weighted images: influence of T2-shine-through and T2-blackout effects. AJNR Am J Neuroradiol 26: 236–241.
[33]
Sasaki M, Yamada K, Watanabe Y, Matsui M, Ida M, et al. (2008) Variability in absolute apparent diffusion coefficient values across different platforms may be substantial: a multivendor, multi-institutional comparison study. Radiology 249: 624–630.
